State Key Laboratory of Respiratory Disease, Guangzhou Key Laboratory of Tuberculosis Research, Institute of Pulmonary Diseases, Guangzhou Chest Hospital, Institute of Tuberculosis, Guangzhou Medical University, 62 Hengzhigang Rd, Yuexiu District, Guangzhou, 510095, People's Republic of China.
School of Public Health, Sun Yat-sen University, Shen Zhen, China.
BMC Infect Dis. 2024 Sep 27;24(1):1037. doi: 10.1186/s12879-024-09939-0.
Tuberculosis (TB) remains a persistent threat to global public health and traditional treatment monitoring approaches are limited by their potential for contamination and need for timely evaluation. Therefore, new biomarkers are urgently required for monitoring the treatment efficacy of TB.
This study aimed to elucidate the levels of CXCL10 and CXCL9 in pulmonary TB patients who underwent anti-TB treatment. The data was acquired from five databases, including PubMed, Ovid, Web of Science, Embase, and the Cochrane Library. A meta-analysis of CXCL10 data from all time points was conducted. Furthermore, a trend meta-analysis of temporal data of CXCL10 and CXCL9 from multiple time points was also performed.
It was revealed that patients who responded poorly to anti-TB treatment had higher serum levels relative to those who responded well (SMD: 1.23, 95% CI: -0.37-2.84) at the end of intensive treatment (2 months). Furthermore, heterogeneity was observed in these results, which might be because patients with a prior history of TB and different treatment monitoring methods than those selected in this study were also included. The analysis of alterations in CXCL10 and CXCL9 levels since the last collection time points indicated that their levels reduced with time.
In summary, the study revealed that reductions in CXCL10 levels during the first two months of anti-TB treatment are correlated with treatment responses. Furthermore, decreasing levels of CXCL9 during the treatment suggest that it may also serve as a biomarker with a similar value to CXCL10. Future in-depth studies are thus warranted to further probe the relevance of CXCL10 and CXCL9 in monitoring the treatment efficacy of TB.
结核病（TB）仍然是全球公共卫生的持续威胁，传统的治疗监测方法受到污染的可能性和及时评估的需要的限制。因此，迫切需要新的生物标志物来监测结核病的治疗效果。
本研究旨在阐明接受抗结核治疗的肺结核患者中 CXCL10 和 CXCL9 的水平。数据来自五个数据库，包括 PubMed、Ovid、Web of Science、Embase 和 Cochrane Library。对所有时间点的 CXCL10 数据进行了荟萃分析。此外，还对多个时间点的 CXCL10 和 CXCL9 的时间数据进行了趋势荟萃分析。
结果表明，在强化治疗（2 个月）结束时，对抗结核治疗反应不佳的患者的血清水平高于反应良好的患者（SMD：1.23，95%CI：-0.37-2.84）。此外，这些结果存在异质性，这可能是因为纳入了既往有结核病病史和治疗监测方法与本研究不同的患者。自上次采集时间点以来 CXCL10 和 CXCL9 水平变化的分析表明，它们的水平随时间降低。
总之，本研究表明，抗结核治疗前两个月 CXCL10 水平的降低与治疗反应相关。此外，治疗过程中 CXCL9 水平的降低表明它也可能作为与 CXCL10 具有相似价值的生物标志物。因此，需要进一步进行深入研究，以进一步探讨 CXCL10 和 CXCL9 在监测结核病治疗效果中的相关性。
Zotero 插件
